We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Baseline quality of life as a prognostic survival tool in patients receiving sunitinib for metastatic renal cell carcinoma.
- Authors
Cella, D; Bushmakin, A G; Cappelleri, J C; Charbonneau, C; Michaelson, M D; Motzer, R J
- Abstract
In a randomized phase III trial of sunitinib vs interferon-alfa (IFN-α) in metastatic renal cell carcinoma (mRCC), better baseline quality of life (QoL) was predictive of longer survival. Using this dataset, we have developed a novel prognostic tool that establishes a relationship between baseline QoL scores and median survival time.
- Publication
British journal of cancer, 2012, Vol 106, Issue 4, p646
- ISSN
1532-1827
- Publication type
Journal Article
- DOI
10.1038/bjc.2011.589